Contributions of water transfer energy to protein‐ligand association and dissociation barriers: Watermap analysis of a series of p38α MAP kinase inhibitors

In our previous work, we proposed that desolvation and resolvation of the binding sites of proteins can serve as the slowest steps during ligand association and dissociation, respectively, and tested this hypothesis on two protein‐ligand systems with known binding kinetics behavior. In the present work, we test this hypothesis on another kinetically‐determined protein‐ligand system—that of p38α and eight Type II BIRB 796 inhibitor analogs. The kon values among the inhibitor analogs are narrowly distributed (104 ≤ kon ≤ 105 M−1 s−1), suggesting a common rate‐determining step, whereas the koff values are widely distributed (10−1 ≤ koff ≤ 10−6 s−1), suggesting a spectrum of rate‐determining steps. We calculated the solvation properties of the DFG‐out protein conformation using an explicit solvent molecular dynamics simulation and thermodynamic analysis method implemented in WaterMap to predict the enthalpic and entropic costs of water transfer to and from bulk solvent incurred upon association and dissociation of each inhibitor. The results suggest that the rate‐determining step for association consists of the transfer of a common set of enthalpically favorable solvating water molecules from the binding site to bulk solvent. The rate‐determining step for inhibitor dissociation consists of the transfer of water from bulk solvent to specific binding site positions that are unfavorably solvated in the apo protein, and evacuated during ligand association. Different sets of unfavorable solvation are evacuated by each ligand, and the observed dissociation barriers are qualitatively consistent with the calculated solvation free energies of those sets.

[1]  Nonequilibrium kinetics of a cyclic GMP-binding protein in dictyostelium discoideum , 1982, The Journal of cell biology.

[2]  Harald Schwalbe,et al.  NMR characterization of kinase p38 dynamics in free and ligand-bound forms. , 2006, Angewandte Chemie.

[3]  Pathway and Mechanism of Drug Binding to G-Protein-Coupled Receptors , 2012 .

[4]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[5]  W. Sherman,et al.  Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization , 2011, Proteins.

[6]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[7]  A. J. Clark The reaction between acetyl choline and muscle cells , 1927, The Journal of physiology.

[8]  C. Pargellis,et al.  The kinetics of binding to p38MAP kinase by analogues of BIRB 796. , 2003, Bioorganic & medicinal chemistry letters.

[9]  R Abagyan,et al.  Evaluating the energetics of empty cavities and internal mutations in proteins , 1997, Protein science : a publication of the Protein Society.

[10]  F. J. Luque,et al.  Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. , 2011, Journal of the American Chemical Society.

[11]  Robert Abel,et al.  Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.

[12]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[13]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[14]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[15]  R. Dror,et al.  A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.

[16]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[17]  C. Wood,et al.  Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers , 2002 .

[18]  P. Bartlett,et al.  Possible role for water dissociation in the slow binding of phosphorus-containing transition-state-analogue inhibitors of thermolysin. , 1987, Biochemistry.

[19]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[20]  B. Lee,et al.  Properties of the protein matrix revealed by the free energy of cavity formation. , 1996, Structure.

[21]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[22]  Woody Sherman,et al.  High‐energy water sites determine peptide binding affinity and specificity of PDZ domains , 2009, Protein science : a publication of the Protein Society.

[23]  R. Farid,et al.  The translocation kinetics of antibiotics through porin OmpC: Insights from structure‐based solvation mapping using WaterMap , 2013, Proteins.

[24]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[25]  Woody Sherman,et al.  New hypotheses about the structure–function of proprotein convertase subtilisin/kexin type 9: Analysis of the epidermal growth factor‐like repeat A docking site using WaterMap , 2010, Proteins.

[26]  R. Copeland,et al.  Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.

[27]  F. Bosch,et al.  The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel Prize , 2008, Pharmacology.

[28]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[29]  Albert C. Pan,et al.  Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.

[30]  B. Berne,et al.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.

[31]  L. Limbird Cell Surface Receptors: A Short Course on Theory and Methods , 1986, Springer US.

[32]  W. Sherman,et al.  Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters , 2010, ChemMedChem.